

[Mesna](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.5. Supportive medicines](#)

Codes ATC: [V03AF01](#)

Indication

Unspecified malignant neoplasms of ill-defined or unspecified sites Code ICD11: [2D9Z](#)

INN

Mesna

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg ; 600 mg

Historique des statuts LME

Ajouté pour la première fois en 2009 ([TRS 958](#))

Retiré en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Mesna](#)

DrugBank

[Mesna \(Coenzyme M\)](#)

Résumé des preuves et recommandation du comité d'experts

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of mesna was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for mesna for more information.